RESECT is an ongoing international, multicentre, observational study including all consecutive new cases of BC scheduled for TURBT (> 17,000 patients included as of June 1st, 2023). Patients were excluded if they presented a preoperative imaging of a muscle invasive bladder cancer (MIBC), missing data, or if they had not yet had their first cystoscopic check-up after TURBT. The quality criteria used were: presence of detrusor muscle (DM+), use of single instillation intra-vesical chemotherapy given within 24 hours (SI-IVC-24), completeness of resection documented, and if all of the tumor number, size, and location were documented in the operation note. A mixed-effects multivariate logistic regression was used for the analysis of the early recurrence rate (defined by the first cystoscopy post TURBT).
Data from 4597 patients having TURBT for first tumour were extracted from 186 sites. Regarding the TURBT quality criteria, the median achievement rate per site was 71.4% for DM+, 43.8% for SI-IVC-24, 72.4% for documenting resection completeness,s, and 79.6% for documenting all tumor features. with a significant difference in achievement between the sites (< 0.05). The median recurrence rate by site was 12% and 27% for low-grade and high-grade tumors, respectively. After adjusting for tumor size, number, stag,e, and grade (significantly and independently associated with early recurrences), a significant difference in the early recurrence rate between the centers (< 0.0001) was shown.
In summary, there was significant variation in TURBT quality criteria and in the early recurrence rate of NMIBC after TURBT surgery between sites that could not be explained by currently understood tumor features.
Presented by: Gautier Marcq, Urology Department, Claude Huriez Hospital, CHU Lille, Lille, France
Written by: Stephen B. Williams, MD, MBA, MS @SWilliams_MD on Twitter during the International Bladder Cancer Network (IBCN) Annual Meeting, September 29-30, 2023, Montreal, Canada